Apollomics, Inc.

What they do

Apollomics Inc. is a Cayman Islands-incorporated biopharmaceutical company focused on the discovery and development of oncology therapies. It operates through subsidiaries and is headquartered in Foster City, California. The company's Class A Ordinary Shares and warrants trade on The Nasdaq Stock Market LLC.

Revenue drivers

• Product candidates — The company is developing oncology product candidates; no product revenue is disclosed in the filing excerpt.
• Licensing or collaboration arrangements — The filing excerpt does not disclose specific licensing or collaboration revenue sources.
• Grants or other income — The excerpt does not provide details on grant revenue or other income streams.

Recent performance

The provided filing excerpt does not include financial results figures for the fiscal year ended December 31, 2025. As of April 24, 2026, the company had 2,196,052 Class A Ordinary Shares outstanding. No revenue, net income, or cash position figures are available in the excerpt.

Strategy

The filing excerpt does not contain specific statements about the company's strategy, investments, or priorities. The document indicates it is an annual report on Form 20-F for the fiscal year ended December 31, 2025, but no strategic details are included in the excerpt.

Risks

• Clinical development risk — As a clinical-stage biopharmaceutical company, Apollomics faces risks related to the success of its product candidates in clinical trials.
• Regulatory approval risk — The company's product candidates require regulatory approvals, which may not be obtained.
• Financing risk — The company may need additional capital to fund its operations and development programs.
• Market and competition risk — The oncology therapy market is highly competitive with many established and emerging players.

Outlook

The filing excerpt does not include management's outlook or forward-looking guidance. No specific statements about future plans or expectations are provided in the excerpt.